权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Estrogen Administration for the Treatment of NASH in Postmenopausal Women

雌激素治疗绝经后妇女 NASH

基本信息

批准号：
10307423
负责人：
Miriam Antoinette Bredella
金额：
$ 73.37万
依托单位：
MASSACHUSETTS GENERAL HOSPITAL
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-08-01 至 2026-05-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10307423
关键词：
ADD-1 protein Age Animals Biopsy CD8-Positive T-Lymphocytes Cell Lineage Cells Characteristics Cirrhosis Data Development Disease Disease Progression Dose Double-Blind Method ECM receptor Endocrinology Epidemic Estradiol Estrogen Replacement Therapy Estrogen Therapy Estrogens FDA approved Fatty acid glycerol esters Fibrosis Gene Expression Profile Generations Genes Genetic Transcription Gold Hepatic High Prevalence Human IL17 Signaling Pathway Immune Immunologics Immunology Inflammation Lipids Liver Liver Fibrosis Liver diseases Lobular Low Prevalence Machine Learning Magnetic Resonance Spectroscopy Manipulative Therapies Menopause Metabolic Metabolic Diseases Metabolic Pathway Methods Microscopy Obesity Ovariectomy Pathogenesis Pathologic Pathway interactions Placebos Play Positioning Attribute Postmenopause Pre-Clinical Model Premenopause Prevalence Prevention trial Process Prospective Studies Protons Randomized Rattus Research Research Personnel Risk Role Secondary to Technology Testing Tissues United States Woman Work clinically significant design double-blind placebo controlled trial effective therapy elastography experience fibrogenesis immunoregulation improved intrahepatic lipid biosynthesis liver biopsy liver imaging liver transplantation macrophage men multidisciplinary new therapeutic target non-alcoholic fatty liver disease nonalcoholic steatohepatitis novel oxidation patient subsets placebo controlled study primary endpoint prospective randomized placebo controlled study response second harmonic sex single-cell RNA sequencing therapy development transcriptome sequencing transcriptomics transdermal estrogen

项目摘要

PROJECT ABSTRACT Non-alcoholic fatty liver disease (NAFLD) is the most common cause of liver disease worldwide; progression to non-alcoholic steatohepatitis (NASH) cirrhosis occurs in a subset of patients and is the second leading indication for liver transplantation in the United States. The factors leading to the development of NAFLD and progression to nonalcoholic steatohepatitis (NASH), including inflammation and fibrosis, are poorly understood. Moreover, there is a lack of effective therapies for these disorders. Studies in animals and humans suggest that estrogen deficiency may be an important mechanism underlying the development of NAFLD and progression to NASH. However, no prospective, randomized, placebo-controlled studies have examined the impact of estrogen administration on steatosis, inflammation or fibrosis in postmenopausal women with NASH. Our overall hypothesis is that low-dose, transdermal estrogen administration will decrease hepatic fat, inflammation and fibrosis in women with biopsy-proven NASH. Further, we will explore estrogen’s immune and metabolic effects in the liver, including changes at the single-cell level. Aim 1 will test the hypothesis that estradiol administration will decrease fibrosis, inflammation and steatosis in women with biopsy-proven NASH. Aim 2 will determine the impact of estrogen on intrahepatic metabolic pathways and on the transcriptional landscape of intrahepatic immune cells. We hypothesize that estrogen will decrease fibrogenesis, decrease hepatic de novo lipogenesis, and increase lipid beta oxidation. These hypotheses will be tested with a rigorously designed, double-blind, placebo-controlled study of the effects of low-dose transdermal estrogen replacement therapy in postmenopausal women with NASH. State-of-the-art liver imaging, liver biopsies, whole liver transcriptomics and unbiased single cell RNAseq by SeqWell will be leveraged to investigate these hypotheses. We have assembled a team of investigators with extensive research experience in endocrinology (Dr. Miller), NAFLD (Dr. Corey), liver imaging (Dr. Bredella), and hepatic immunology (Dr. Lauer), which is uniquely positioned to carry out this multi-disciplinary proposal. Elucidating the effects of low-dose, transdermal estrogen administration on liver fibrosis, inflammation and steatosis has the potential to further our understanding of this disease process and identify new therapeutic targets where few currently exist.

项目摘要